Stephen Paul West Buys 400,000 Shares of Roquefort Therapeutics plc (LON:ROQ) Stock

Roquefort Therapeutics plc (LON:ROQ) insider Stephen Paul West bought 400,000 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was bought at an average price of GBX 3 ($0.04) per share, with a total value of £12,000 ($15,001.88).

Roquefort Therapeutics Trading Down 14.9 %

Shares of Roquefort Therapeutics stock opened at GBX 2.26 ($0.03) on Thursday. The company’s 50-day moving average price is GBX 4 and its 200-day moving average price is GBX 3.99. The company has a market cap of £2.91 million, a price-to-earnings ratio of -225.50 and a beta of 0.05. Roquefort Therapeutics plc has a 12-month low of GBX 2.15 ($0.03) and a 12-month high of GBX 9.50 ($0.12). The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.